Ontology highlight
ABSTRACT:
SUBMITTER: Yao JC
PROVIDER: S-EPMC4295034 | biostudies-literature | 2010 Jan
REPOSITORIES: biostudies-literature
Yao James C JC Lombard-Bohas Catherine C Baudin Eric E Kvols Larry K LK Rougier Philippe P Ruszniewski Philippe P Hoosen Sakina S St Peter Jessica J Haas Tomas T Lebwohl David D Van Cutsem Eric E Kulke Matthew H MH Hobday Timothy J TJ O'Dorisio Thomas M TM Shah Manisha H MH Cadiot Guillaume G Luppi Gabriele G Posey James A JA Wiedenmann Bertram B
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091123 1
PURPOSE No established treatment exists for pancreatic neuroendocrine tumor (NET) progression after failure of chemotherapy. Everolimus (RAD001), an oral inhibitor of mammalian target of rapamycin, in combination with octreotide has demonstrated encouraging antitumor activity in patients with NETs. PATIENTS AND METHODS This open-label, phase II study assessed the clinical activity of everolimus in patients with metastatic pancreatic NETs who experienced progression on or after chemotherapy. Pati ...[more]